NO20064288L - Tetraazabenzo(E)azulen-derivater og angaloger derav - Google Patents

Tetraazabenzo(E)azulen-derivater og angaloger derav

Info

Publication number
NO20064288L
NO20064288L NO20064288A NO20064288A NO20064288L NO 20064288 L NO20064288 L NO 20064288L NO 20064288 A NO20064288 A NO 20064288A NO 20064288 A NO20064288 A NO 20064288A NO 20064288 L NO20064288 L NO 20064288L
Authority
NO
Norway
Prior art keywords
angalogs
tetraazabenzo
azulene derivatives
compounds
azulene
Prior art date
Application number
NO20064288A
Other languages
English (en)
Inventor
Kimberly O'keefe Cameron
Richard Louis Elliott
Marlys Hammond
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20064288L publication Critical patent/NO20064288L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det beskrives CCK-A-agonister av Formel (1) hvor Rl-R4, A, B, X, D, E og G er som definert i beskrivelsen, og også, blant annet, farmasøytiske materialer inneholdende · forbindelsene, og fremgangsmåter for anvendelse av forbindelsene og materialene. Forbindelsene er nyttige for behandling av obesitet.
NO20064288A 2004-05-25 2006-09-21 Tetraazabenzo(E)azulen-derivater og angaloger derav NO20064288L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57403304P 2004-05-25 2004-05-25
PCT/IB2005/001469 WO2005116034A1 (en) 2004-05-25 2005-05-13 Tetraazabenzo[e]azulene derivatives and analogs thereof

Publications (1)

Publication Number Publication Date
NO20064288L true NO20064288L (no) 2006-10-23

Family

ID=34967684

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064288A NO20064288L (no) 2004-05-25 2006-09-21 Tetraazabenzo(E)azulen-derivater og angaloger derav

Country Status (26)

Country Link
US (2) US7265104B2 (no)
EP (1) EP1753766A1 (no)
JP (1) JP4069159B2 (no)
CN (1) CN1950374A (no)
AP (1) AP2006003768A0 (no)
AR (1) AR049187A1 (no)
AU (1) AU2005247693A1 (no)
BR (1) BRPI0510273A (no)
CA (1) CA2568056A1 (no)
CR (1) CR8753A (no)
EA (1) EA010888B1 (no)
EC (1) ECSP067025A (no)
GE (1) GEP20094723B (no)
GT (1) GT200500119A (no)
IL (1) IL178220A0 (no)
MA (1) MA28605B1 (no)
NL (1) NL1029105C2 (no)
NO (1) NO20064288L (no)
PA (1) PA8634101A1 (no)
PE (1) PE20060363A1 (no)
SV (1) SV2006002127A (no)
TN (1) TNSN06386A1 (no)
TW (1) TWI297688B (no)
UA (1) UA84208C2 (no)
UY (1) UY28915A1 (no)
WO (1) WO2005116034A1 (no)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060177438A1 (en) * 2005-02-08 2006-08-10 New England Medical Center Methods of altering absorption of hydrophobic compounds
JP2009507050A (ja) * 2005-09-08 2009-02-19 ガストロテック・ファルマ・アクティーゼルスカブ 胆道ジスキネジーおよび／または胆道痛／不快の治療のためのｇｌｐ−１分子の使用
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
KR20090064478A (ko) 2006-11-13 2009-06-18 화이자 프로덕츠 인크. 디아릴, 디피리디닐 및 아릴-피리디닐 유도체, 및 이들의 용도
ATE484506T1 (de) * 2006-12-11 2010-10-15 Merck Sharp & Dohme Substituierte diazepin-sulfonamide als bombesin- rezeptor-subtyp-3-modulatoren
US20100144715A1 (en) * 2007-02-28 2010-06-10 Hoyt Scott B Substituted Benzodiazepinones, Benzoxazepinones and Benzothiazepinones as Sodium Channel Blockers
US20100317642A1 (en) * 2007-10-15 2010-12-16 Inventis Dds Pvt Limited Pharmaceutical composition of orlistat
EP2214481B1 (en) 2007-10-15 2019-05-01 United Animal Health, Inc. Method for increasing performance of offspring
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
PT2356123E (pt) * 2008-11-13 2012-10-31 Hoffmann La Roche Espiro-5,6-di-hidro-4h-2,3,5,10b-tetra-azabenzo[ e]azulenos
ES2391374T3 (es) * 2008-11-18 2012-11-23 F. Hoffmann-La Roche Ag Alquilciclohexiléteres de dihidrotetraazabenzoazulenos
ES2431279T3 (es) * 2008-11-28 2013-11-25 F. Hoffmann-La Roche Ag Arilciclohexiléteres de dihidro-tetraazabenzoazulenos para uso como antagonistas del receptor V1A de la vasopresina
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
EP2389374A1 (en) 2009-01-20 2011-11-30 Pfizer Inc. Substituted pyrazinone amides
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
TW201040174A (en) 2009-02-03 2010-11-16 Pfizer 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one derivatives
CA2749893A1 (en) 2009-02-04 2010-08-12 Pfizer Inc. 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives
EP2406230A1 (en) 2009-03-11 2012-01-18 Pfizer Inc. Substituted indazole amides and their use as glucokinase activators
GEP20156239B (en) 2009-03-11 2015-01-26 Pfizer Benzofuranyl derivatives used as glucokinase inhibitors
EP2408780A2 (en) 2009-03-20 2012-01-25 Pfizer Inc. 3-oxa-7-azabicycloý3.3.1¨nonanes
BRPI1014636A2 (pt) 2009-06-05 2016-04-05 Pfizer moduladores de gpr 119
US8785608B2 (en) 2009-08-26 2014-07-22 Sanofi Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
CA2772188A1 (en) 2009-09-23 2011-03-31 Pfizer Inc. Gpr 119 modulators
GEP20146104B (en) 2009-11-02 2014-05-27 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
JP2013510191A (ja) 2009-11-10 2013-03-21 ファイザー・インク Ｎ−２ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害薬
CU24077B1 (es) 2009-11-10 2015-03-30 Pfizer DERIVADOS DE N1-PIRAZOLOESPIROCETONA ÚTILES COMO INHIBIDORES DE ACETIL-CoA CARBOXILASA
WO2011061679A1 (en) 2009-11-23 2011-05-26 Pfizer Inc. Imidazo-pyrazoles as gpr119 inhibitors
US20110160143A1 (en) * 2009-12-28 2011-06-30 Perricone Nicholas V Topical Acyl Glutathione Psoriasis Compositions
ME02330B (me) 2010-03-19 2016-06-20 Pfizer Derivati 2,3-dihidro-1h-inden-1-il-2,7-diazaspir0[3.6]nonana i njihova upotreba kao antagonista ili inverznih agonista grelinskog receptora
WO2011123678A2 (en) 2010-03-31 2011-10-06 Arqule, Inc. Substituted benzo-pyrido-triazolo-diazepine compounds
US8420633B2 (en) 2010-03-31 2013-04-16 Hoffmann-La Roche Inc. Aryl-cyclohexyl-tetraazabenzo[e]azulenes
US8461151B2 (en) 2010-04-13 2013-06-11 Hoffmann-La Roche Inc. Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes
US8492376B2 (en) 2010-04-21 2013-07-23 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8481528B2 (en) 2010-04-26 2013-07-09 Hoffmann-La Roche Inc. Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8513238B2 (en) 2010-05-10 2013-08-20 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes
WO2011158149A1 (en) 2010-06-18 2011-12-22 Pfizer Inc. 2-(3,5-disubstitutedphenyl)pyrimidin-4(3h)-one derivatives
PT2621493T (pt) 2010-09-30 2016-11-14 Pfizer Inibidores de n1-pirazolospirocetona acetil-coa carboxilase
KR20150006899A (ko) 2010-10-29 2015-01-19 화이자 인코포레이티드 N1/N2-락탐 아세틸-CoA 카복실라아제 억제제
BR112013016033A2 (pt) 2010-12-23 2018-06-05 Pfizer moduladores do receptor de glucagon
EA023517B1 (ru) 2011-02-08 2016-06-30 Пфайзер Инк. Модуляторы глюкагонового рецептора
WO2012114342A1 (en) * 2011-02-23 2012-08-30 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
CN103492388A (zh) 2011-04-22 2014-01-01 辉瑞大药厂 用作乙酰辅酶a羧化酶抑制剂类的吡唑并螺酮衍生物
WO2013011402A1 (en) 2011-07-15 2013-01-24 Pfizer Inc. Gpr 119 modulators
BR112014000288A2 (pt) 2011-07-22 2017-01-10 Pfizer moduladores do receptor de glucagon de quinolinila
EP2751116B1 (en) 2011-08-31 2016-10-12 Pfizer Inc Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2869587A1 (en) 2012-04-06 2013-10-10 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6110937B2 (ja) 2012-05-04 2017-04-05 ファイザー・インク ＡＰＰ、ＢＡＣＥ１、およびＢＡＣＥ２の阻害剤としての複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
EP2867236B1 (en) 2012-06-29 2017-06-14 Pfizer Inc Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
JP2015529239A (ja) 2012-09-20 2015-10-05 ファイザー・インク アルキル置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
EP2931731A1 (en) 2012-12-11 2015-10-21 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
EP2935282A1 (en) 2012-12-19 2015-10-28 Pfizer Inc. CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
CA2897678A1 (en) 2013-02-13 2014-08-21 Pfizer Inc. Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
ES2665153T3 (es) 2013-10-09 2018-04-24 Pfizer Inc. Antagonistas del receptor EP3 de prostaglandina
CN103664675B (zh) * 2013-11-27 2016-05-18 浙江省诸暨合力化学对外贸易有限公司 一种2-氯-n-(4-氟苯基)-n-异丙基乙酰胺的制备方法
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
SI3119757T1 (en) 2014-03-17 2018-08-31 Pfizer Inc. DIACILGLICEROL-ACILTRANSFERAZE 2 BINDERS FOR THE USE IN THE TREATMENT OF PRECIOUS AND RELATED DISEASES
AU2015245260A1 (en) 2014-04-10 2016-10-06 Pfizer Inc. 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides
WO2016092413A1 (en) 2014-12-10 2016-06-16 Pfizer Inc. Indole and indazole compounds that activate ampk
JP2017538769A (ja) 2014-12-22 2017-12-28 ファイザー・インク プロスタグランジンｅｐ３受容体の拮抗薬
HUE059372T2 (hu) 2015-06-17 2022-11-28 Pfizer Triciklusos vegyületek és azok alkalmazása foszfodiészteráz inhibitorként
WO2017046675A1 (en) 2015-09-14 2017-03-23 Pfizer Inc. Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors
BR112018003489A2 (pt) 2015-09-24 2018-09-25 Pfizer n-[2-(2-amino-6,6-dissubstituído-4,4a,5,6-tetra-hidropirano[3,4-d][1,3]tiazin-8a(8h)-il)-1,3-tiazol-4-il]amidas
WO2017051303A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
WO2017051294A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors
UA121271C2 (uk) 2015-12-29 2020-04-27 Пфайзер Інк. Заміщені 3-азабіцикло[3.1.0]гексани як інгібітори кетогексокінази
CN105524069A (zh) * 2016-02-25 2016-04-27 江苏理工学院 一种新型胆囊收缩毒受体拮抗剂类似物及其合成方法
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
MX2021002428A (es) 2018-08-31 2023-01-02 Pfizer Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas.
EP3972596A1 (en) 2019-05-20 2022-03-30 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
AU2020363377A1 (en) 2019-10-07 2022-04-21 Kallyope, Inc. GPR119 agonists
CN112573494B (zh) * 2020-12-23 2022-06-21 西南石油大学 一种利用水合物法的氦精制装置
WO2023026180A1 (en) 2021-08-26 2023-03-02 Pfizer Inc. Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2318673A1 (de) * 1973-04-13 1974-11-07 Boehringer Sohn Ingelheim Neue substituierte triazolo-1,5benzodiazepine
IE41197B1 (en) * 1973-05-29 1979-11-07 Squibb & Sons Inc 4h-s-triazolo (4,3-a)(1,5)benzodiazepin-5-ones
US4080323A (en) 1977-03-07 1978-03-21 Hoffmann-La Roche Inc. Imidazo [1,5-a][1,5] benzodiazepines
US4118386A (en) 1977-04-04 1978-10-03 Hoffmann-La Roche Inc. Synthesis of imidazo[1,5-a]diazepine-3-carboxylates
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
DK0580860T4 (da) 1991-04-16 2005-03-21 Nippon Shinyaku Co Ltd Fremgangsmåde til fremstilling af en fast dispersion
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
GB9307833D0 (en) 1993-04-15 1993-06-02 Glaxo Inc Modulators of cholecystokinin and gastrin
FR2716195B1 (fr) 1994-02-14 1996-06-21 Sanofi Sa Dérivés de 3-acylamino-5-phényl-1,4-benzodiazépin-2-one polysubstitués, leur procédé de préparation et les compositions pharmaceutiques les contenant.
HUT76135A (en) 1994-04-14 1997-06-30 Glaxo Wellcome Inc Cholecystokinin and gastrin modulating 5-heterocyclic-1,5-benzodiazepines
PE27497A1 (es) * 1994-04-15 1997-08-07 Glaxo Inc Derivados de 1,5 benzodiazepina
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
WO2000027845A1 (en) 1998-11-10 2000-05-18 Merck & Co., Inc. Spiro-indolines as y5 receptor antagonists
AR022044A1 (es) 1999-05-06 2002-09-04 Glaxo Group Ltd Derivados de 1,5-benzodiazepina
US6462053B1 (en) 1999-08-20 2002-10-08 Banyu Pharmaceutical Co., Ltd. Spiro compounds
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
US20050033048A1 (en) 2000-12-12 2005-02-10 Rajagopal Bakthavatchalam Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
US6924291B2 (en) 2001-01-23 2005-08-02 Merck & Co., Inc. Process for making spiro isobenzofuranone compounds
US6605720B1 (en) 2002-01-28 2003-08-12 Merck & Co., Inc. Process for making spirolactone compounds

Also Published As

Publication number Publication date
JP2008500326A (ja) 2008-01-10
US7358242B2 (en) 2008-04-15
GT200500119A (es) 2006-01-12
CA2568056A1 (en) 2005-12-08
PA8634101A1 (es) 2006-06-02
UY28915A1 (es) 2005-12-30
US20050267100A1 (en) 2005-12-01
EP1753766A1 (en) 2007-02-21
EA200601773A1 (ru) 2007-06-29
JP4069159B2 (ja) 2008-04-02
TWI297688B (en) 2008-06-11
NL1029105A1 (nl) 2005-11-30
MA28605B1 (fr) 2007-05-02
NL1029105C2 (nl) 2006-06-13
CN1950374A (zh) 2007-04-18
IL178220A0 (en) 2006-12-31
EA010888B1 (ru) 2008-12-30
US20070265193A1 (en) 2007-11-15
SV2006002127A (es) 2006-02-15
PE20060363A1 (es) 2006-05-08
UA84208C2 (en) 2008-09-25
AP2006003768A0 (en) 2006-10-31
AR049187A1 (es) 2006-07-05
CR8753A (es) 2006-12-13
WO2005116034A1 (en) 2005-12-08
ECSP067025A (es) 2006-12-29
TNSN06386A1 (fr) 2008-02-22
BRPI0510273A (pt) 2007-10-30
TW200609235A (en) 2006-03-16
US7265104B2 (en) 2007-09-04
AU2005247693A1 (en) 2005-12-08
GEP20094723B (en) 2009-07-10

Similar Documents

Publication Publication Date Title
NO20064288L (no) Tetraazabenzo(E)azulen-derivater og angaloger derav
NO20063576L (no) 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
NO20050828L (no) lndol-3-svovelderivater
NO20025821L (no) 2-aminokarbonyl-9H-purinderivater
ATE449604T1 (de) Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
NO20073663L (no) Tiazol-4-karboksamid-derivater som mGluR5 antagonister
GEP20094605B (en) Pyrazole derivatives, compositions containing such compounds and methods of use thereof
DE60328010D1 (de) Heterocyclische verbindungen
NO20054329L (no) Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
NO20054787L (no) Indenderivater som farmasotiske midler
NO330968B1 (no) Ny fremgangsmate for syntesen av (1S)-4,5-dimetoksy-1-(metylaminometyl)-benzocyklobutan og addisjonssalter derav, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
SE0200920D0 (sv) Novel compounds
NO20050741L (no) Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den
DK1499590T3 (da) Piperidinderivater som kaliumkanalblokkere
MX2007012212A (es) 1h-pirazol 4-carboxilamidas, su preparacion y su uso como 11-beta-hidroxiesteroide deshidrogenasa.
NO20070570L (no) Forbindelser.
NO20083480L (no) Piperidinoylpyrrolidiner som melanokortin type 4 reseptor agonister
NO20062629L (no) Oksazolderivater av tetrackliner
IL173810A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
SE0401762D0 (sv) Novel compounds
NO20064351L (no) Caspaseinhibitorer og anvendelser derav
TW200635917A (en) Novel compounds
MX2007007025A (es) Nuevos derivados de hidantoina como inhibidores de metaloproteinasa.
ATE449069T1 (de) Aminopropanolderivate

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application